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Abstract
Objectives: Whereas the importance of family history (FH) is widely recognized in cardiovascular risk assessment, its full
potential could be underutilized, when applied with its current simple guidelines-based definition (cFH): presence of
premature cardiovascular disease (CVD) in a first-degree relative. We tested the added value of a new, extended family
history definition (eFH), also taking into account later onset of disease, second-degree relatives and number of affected
relatives, on profiling cardiovascular risk and atherosclerotic burden in the general population.
Design: longitudinal population study.
Setting: random, representative population sample from Erpe-Mere and Nieuwerkerken (Belgium, primary care).
Subjects: 2524 male/female volunteers, aged 35–55 years, free from overt CVD.
Main outcome measures: Subjects were extensively phenotyped including presence of atherosclerosis (ultrasound) and a
newly developed FH questionnaire (4 generations).
Results: Compared to cFH, eFH was superior in predicting an adverse risk profile (glycemic state, elevated blood pressure,
lipid abnormalities, presence of metabolic syndrome components) and presence of atherosclerosis (all age & sex-adjusted
p,0.05). Unlike cFH, eFH remained a significant predictor of subclinical atherosclerosis after adjusting for confounders. Most
relations with eFH were not graded but showed clear informational breakpoints, with absence of CVD (including late onset)
in any first-degree relative being a negative predictor of atherosclerosis, and a particularly interesting phenotype for further
study.
Conclusions: A novel, extended FH definition is superior to the conventional definition in profiling cardiovascular risk and
atherosclerotic burden in the general population. There remain clear opportunities to refine and increase the performance
and informational content of this simple, readily-available inexpensive tool.
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Introduction
Cardiovascular disease (CVD) aggregates in families [1,2,3,4].
Family history (FH) represents the integration of risk within a
family from shared genetic susceptibilities and familial clustering of
environmental exposures, lifestyles and behaviours [5]. Accurately
defining FH of CVD will have increasing importance in the
prevention and treatment of CVD in the post-genome era [6,7,8].
Although the term FH is frequently used, there is no common
definition [8]. Nearly all definitions are assessments of either ‘‘any
FH of CVD’’ or ‘‘CVD history in a first-degree relative’’ and are
usually treated as a simple binary variable according to the
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occurrence or non-occurrence of disease [9,10]. The current most
common definition used in guidelines (cFH) is occurrence of
premature CVD (,55 years for men and,65 years for women) in
a first-degree relative [11]. Taking into account additional
elements could extend the information content of ‘‘family history’’.
Multiple approaches attempting to define which are the key
elements of FH have been studied, including: age at onset
(premature, late occurrence of disease), degree of relationship (first,
second-degree), type of relative (sibling, parent), number of
affected relatives and lineage (maternal, paternal) [10,12,13,14].
In first-degree relatives coronary heart disease (CHD) risk is
greater given younger ages of onset, but -to a lesser extent- also
late-onset CHD is associated with early-onset CHD in the
proband [10,12,13]. Furthermore, sibling history of CHD might
be a stronger risk factor than parental history [10,15,16]. CHD in
second-degree relatives is associated with early-onset CHD in the
proband, especially with more than one affected relative or with
early-onset disease [12]. Increased CHD risk is associated with
increasing numbers of first- and second-degree relatives with CHD
[10,12]. With regard to lineage the evidence for differential
transmission of CHD is far from uniform [10,12,13,17].
Taking into account these key additional elements, we propose a
novel, extended FH definition (Asklepios eFH) and define its
additional value in describing the risk factor profile and presence
of subclinical cardiovascular damage in a large representative
population sample.
Methods
Ethics Statement
The study complies with the declaration of Helsinki, the
protocol was approved by the ethical committee of the Ghent
University Hospital and all subjects gave written informed consent.
Study Population
Subjects were derived from the Asklepios Study, an extensively
phenotyped population-representative random sample of 2524
male/female volunteers aged 35–55 years, from the Belgian
communities of Erpe-Mere and Nieuwerkerken, free from
clinically overt CVD at baseline. An in-depth description of the
ASKLEPIOS study protocol has been published [18].
Exclusion criteria were: 1. clinical presence of atherosclerosis/
atherothrombosis; 2. major concomitant illness; 3. Diabetes
mellitus (DM) type 1, and type 2 if proven macro-vasculopathy
or significant renal impairment; 4. conditions precluding accurate
haemodynamic assessment (atrial fibrillation, pregnancy); 5.
inability to provide informed consent [18].
Participant Examination: Overview
After obtaining written informed consent, review of question-
naire data and rest, measurements included: basic clinical data,
blood sampling and cardiac and vascular echography. All
measurements were single observer. Blood pressure (BP) was
recorded using cuff-patient matched bilateral triplicate measure-
ments on a sitting subject using a validated oscillometric device
(Omron HEM-907). Body mass index (BMI) was calculated as
weight (kg)/height (m)2. Metabolic syndrome (MS) was defined
according to the revised ATP-III criteria [19].
Biochemical Analyses
All subjects were fasting, had refrained from smoking for at least
6 hours and were screened for intercurrent infection/inflamma-
tion before blood sampling (in which case blood sampling was
postponed). Serum parameters were measured on a Modular P
automated system (Roche Diagnostics, Mannheim, Germany), in
an ISO 9002 certified reference laboratory. Impaired fasting
glycemia (IFG) denotes a fasting glucose level $100 mg/dl and
,126 mg/dl (diabetes). High-sensitive C-reactive protein (hs-
CRP) concentrations were measured by a high-sensitive, particle-
enhanced immunoturbidimetric method (Roche Diagnostics,
Mannheim, Germany) [20]. Coefficient of variation (CV) of all
tests described above was ,3.0%. Serum oxidized low-density
lipoprotein concentration was measured by a sandwich enzyme-
linked immunosorbent assay (Mercodia, Uppsala, Sweden)
[21,22]. Total CV was ,7.4%.
Subclinical Cardiovascular Damage
Carotid and femoral arteries were carefully scanned bilaterally
for the presence of plaque (focal protrusion .50% compared to
adjacent sites, absolute thickness .1.5 mm). Intima-media thick-
ness (IMT) was defined as the distance from the leading edge of
the lumen-intima interface to the leading edge of the media-
adventitia interface, measured in end-diastole, at the far wall, 1–
2 cm before the bifurcations [23]. Intra-observer coefficient of
variation was 5.2% [24]. Atherosclerosis was defined as a carotid
or femoral IMT $0.9 mm and/or presence of carotid or femoral
plaque.
Family History
The Asklepios FH Questionnaire (see Questionnaire S1),
created for this study, provided data on the occurrence of CVD
in 4 generations of the respondent’s genetic family (parents,
grandparents, siblings and offspring). As the participants had
several days to complete the questionnaire, they could obtain
additional information from family members. The study nurse
together with the subject reviewed the questionnaire during the
visit. For all family members, respondents provided the year of
birth and the year and cause of death. The questionnaire further
queries for the occurrence of fatal and nonfatal CVD events:
myocardial infarction, coronary revascularisation, peripheral
vascular intervention of inguinal or lower limb arteries, stroke,
carotid revascularisation or sudden cardiac death.
We propose a more comprehensive extended FH construct and
divided participants into 3 categories according to their FH: high,
moderate and low risk (Fig. 1) [25]. The eFH definition takes into
account additional elements such as age at onset of disease
(premature, late occurrence), degree of relationship (first, second-
degree (grandparents)) and number of affected relatives. The high-
risk category was based on literature review and practice
guidelines [11,12]. The low-risk category was adapted from
literature and a stratification model from Scheuner et al. used to
address common chronic diseases in a prenatal setting and
subsequently shown to be useful in assessing FH in internal
medicine [6,10,12,13,26]. All other subjects where categorized as
moderate risk.
Statistical Analysis
Statistical analysis was performed using SPSS Statistics 20.0.
(SPSS Inc., Ill. USA) and R (R-2.15.3, www.r-project.org). In
Table 1, we compared the anthropometric, biochemical, meta-
bolic, lifestyle, and other classic cardiovascular risk factors in the
different FH categories. As most of these variables were continuous
variables, we used age- and sex-adjusted general linear models
(GLM) and data are reported as estimated marginal means (95%
confidence interval). For categorical variables, the differences
between the FH risk categories were calculated by using chi-square
tests.
A Novel Family History Definition
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e63185
We used logistic regression to calculate the adjusted odds ratios
of having atherosclerosis, according cFH and eFH classes (first
age- and sex adjusted and subsequently multivariate adjusted using
confounders age, sex, total cholesterol, HDL-cholesterol, systolic
BP, smoking, DM and BMI). The level of significance was set at
p,0.05; we used a p,0.025 when comparing the eFH classes to
account for multiple testing.
Risk models for presence of atherosclerosis were compared
using the PredictABEL package within R (version 1.2–1, July
2012) [27,28,29]. As the high-risk categories are near identical
in the Asklepios eFH and cFH definitions, the analysis was only
meaningful in the cFH negative group in which we compared a
baseline model including classic cardiovascular risk factors to a
model to which the novel Asklepios eFH definition was added.
The baseline risk model included age, sex, total cholesterol,
HDL-cholesterol, smoking, BMI and diabetes mellitus. We
assessed continuous net reclassification improvement (NRI) and
integrated discrimination improvement (IDI). Since there are no
meaningful risk categories for the presence of atherosclerosis, we
calculated the continuous NRI, which is the most objective
measure of improvement in risk prediction and can be used
universally.
Results
The FH questionnaire was completed by 2491 out of 2524
Asklepios subjects (Fig. 1). For 2151 out of 2491 subjects (86.4%)
all necessary information was available to evaluate FH. We
excluded 340 subjects (13.6%) who could not be correctly classified
because of insufficiently accurate knowledge of their FH. Basic
characteristics and risk factor profile of this unclassifiable group
were similar to the overall population, except for a higher BMI
(26.5 kg/m2 versus 25.8 kg/m2).
According to the cFH definition, 1706 subjects (79.3%) had a
negative FH and 445 (20.7%) a positive FH. The Asklepios eFH
classification categorized 419 subjects (19.5%) as low, 1280
(59.5%) as moderate and 452 (21.0%) as high risk.
The new eFH high-risk group is almost identical to the
guidelines-defined cFH positives (intraclass correlation coefficient
0.995). Seven subjects, categorized as negative in the cFH were
categorized as high risk in the Asklepios eFH (those having $2
second-degree relatives (grandparents) with premature CVD). The
new eFH definition essentially differs from the cFH definition by
sub-stratifying the cFH negative group into two categories in the
eFH: a large moderate risk subgroup and a smaller low risk
subgroup (Fig. 1).
Figure 1. Overview of the distribution of subjects according to the conventional and to the proposed new extended family history
definitions. The graph shows the distribution of participants according to the conventional, guidelines-based definition (cFH) and the proposed
new extended Asklepios family history definition (eFH). The new eFH high-risk group is almost identical to the guidelines-defined cFH positives.
Seven subjects, categorized as negative in the cFH were categorized as high risk in the eFH (those having at least two second-degree relatives
(grandparents) with premature CVD). The new eFH definition mainly differs from the conventional definition (cFH) by sub-stratifying the cFH negative
group into two categories in the eFH: a large moderate-risk subgroup and a smaller low-risk subgroup.
doi:10.1371/journal.pone.0063185.g001
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Novel Asklepios eFH Versus Guidelines-defined cFH
Age and sex-adjusted analyses according to eFH and cFH on
anthropometric, biochemical, metabolic, lifestyle, and other
classic cardiovascular risk factors are shown in Table 1.
In age and sex-adjusted GLM analyses, a FH of CVD (using
either definition) was associated with significantly higher BMI,
systolic and diastolic BP, triglycerides, oxidized LDL-cholesterol,
10-year CVD risk (SCORE) and a significantly lower HDL-
cholesterol.
Furthermore the novel eFH definition (but not cFH) showed
significant associations with glycemic state, non-HDL-cholesterol,
LDL-cholesterol, the number of MS components, and it showed
borderline significant associations with total cholesterol and
fibrinogen.
We subsequently assessed 262 comparisons (using age and sex-
adjusted GLM) of the three categories of the novel eFH (low,
moderate and high risk; Table 1). Most of the additional
information when using the novel eFH definition can be
explained by the newly defined low risk category (Table 1). The
risk profile of the eFH moderate-risk group is not that different
from the eFH high-risk group and the near-identical cFH positive
group. Therefore, the lower risk profile in the cFH negative group
(consisting of eFH low+moderate-risk groups), seems to be mainly
driven by the admixture of the eFH low-risk component (Table 1;
total, LDL- and non-HDL-cholesterol, triglycerides, glycemic
state, number of MS components, oxidized LDL-cholesterol,
systolic BP and 10-year CVD risk).
Subclinical Vascular Damage
Finally, we assessed the burden of subclinical cardiovascular
damage according to both FH definitions. The prevalence of
atherosclerosis according to both FH definitions in our study
population is presented in Fig. 2.
In age- and sex-adjusted logistic regression analyses, taking the
moderate-risk eFH group as the reference category, odds ratios
for prevalent atherosclerosis were 0.67 (95% CI 0.51–0.87,
p = 0.003) in the low-risk eFH group versus the moderate-risk
eFH group. There was no significant increase in prevalent
atherosclerosis when comparing eFH high-risk versus moderate-
risk categories. For the conventional definition, there was no
significant difference on the prevalence of atherosclerosis between
cFH positives versus negatives (OR 1.22, 95%CI 0.96–1.54,
p = 0.106).
In multivariate adjusted analyses, using classical confounding
risk factors (age, sex, total cholesterol, HDL-cholesterol, systolic
BP, smoking, BMI and DM), the odds ratios were 0.74 (95% CI
0.56–0.98) in the low-risk eFH group versus the moderate-risk
eFH group (Fig. 3). Again, no significant increase in prevalent
atherosclerosis was observed when comparing eFH high-risk
versus moderate-risk categories or when using the guidelines
definition.
We performed sensitivity analyses by 1) analyzing the data for
women and men separately, 2) for subjects above and below the
age median (45 years) separately, and 3) corrected for educational
achievement (as a proxy for social class). We also performed the
multivariate analyses by using 1) waist hip ratio and 2) waist
circumference instead of BMI as a marker of obesity. The results
remained essentially unchanged by these further analyses.
Finally, we tested net reclassification improvement (NRI) and
integrated discrimination improvement (IDI) on predicting the
presence (or absence) of atherosclerosis by adding the novel eFH
definition to a multivariable prediction model including age, sex,
systolic blood pressure, total cholesterol, HDL-cholesterol, smok-
ing, BMI and diabetes mellitus in those subjects in the cFH
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negative ( = eFH low and moderate risk) categories. The contin-
uous NRI was significant (0.217 (95% CI 0.120–0.315),
p = 0.00001), the IDI borderline significant (p = 0.068).
Discussion
In this study, we designed and tested a novel extended family
history definition (Asklepios eFH) which: (1) better correlates with
metabolic risk factor burden and; (2) independently predicts the
presence of subclinical atherosclerosis beyond conventional risk
factor burden, unlike cFH assessments. The eFH definition also
shows significant improvement in reclassification for the prediction
of prevalent atherosclerosis. The new definition differs from the
conventional cFH definition in two aspects. First, it includes key
additional elements (identified from literature review) so that the
new eFH definition also takes into account later occurrence of
disease, disease in second-degree relatives (grandparents) and
number of affected relatives. Second, the eFH definition divides
participants into 3 rather than 2 categories (Fig. 1): a high-risk
group, which is almost identical to the guidelines-defined cFH
positive group, and a moderate-risk and novel low-risk group, that
has a manifestly lower prevalence of subclinical atherosclerosis.
The new Asklepios eFH definition is superior in detecting
adverse CVD risk profiles in the general population. It exposes a
significantly greater differential in risk profile than cFH. The eFH
definition (but not the cFH definition) was additionally associated
with unfavourable glycemic and lipid profiles, more components of
the metabolic syndrome and more atherosclerosis. Furthermore,
an important novel finding is that most relations with eFH were
not graded but showed clear informational breakpoints with the
eFH low-risk group being particularly interesting. Much of the
additional information extracted by the novel eFH definition can
be attributed to the presence of this newly defined low-risk
category. The cFH positive group, the eFH high-risk and large
eFH moderate-risk groups have quite similar risk factor profiles
and preclinical atherosclerotic burdens. Separating out the low-
risk category in many cases abolished a large part of the step-up in
adverse risk profiles found in the cFH positive group, suggesting
that the differences between the guidelines positive and negative
groups are (in part) due to the admixture of the eFH low-risk
group to the latter (i.e. some differences are due to a significantly
better risk profile in the eFH low-risk group).
Most importantly, the new eFH definition (but not the
conventional definition) was able to identify presence of athero-
sclerosis beyond conventional risk factor burden, indicating that
FH conveys additional information, not completely characterized
by simply measuring a risk factor profile.
A few studies already showed the value of extending FH beyond
a simple yes/no question about presence of disease in a first-degree
relative [10,12,14]. Scheuner et al. investigated various binary
definitions of FH and found significant associations between a
personal history of CHD and an additional FH that goes beyond
having first-degree relatives with early-onset CHD [12]. In line
with their work we took into account key additional elements in
our new eFH definition, and we elaborated on their dichotomous
definitions by defining a three-tier definition encompassing both
the classic high-risk group, as well as a novel and highly interesting
low-risk group.
Figure 2. Presence of atherosclerosis according to the proposed new extended family history definition (eFH) and the conventional
definition (cFH). Unadjusted data show remarkably less atherosclerosis in the eFH low-risk group (14%) versus the eFH moderate-risk (42%) and
eFH high-risk group (43%). There were no large differences observed in prevalence of atherosclerosis when comparing the cFH positive versus
negative group (43% versus 39%).
doi:10.1371/journal.pone.0063185.g002
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That presence of a positive FH is associated with an adverse risk
profile is largely in agreement with published reports [30,31]. This
familial aggregation of cardiovascular risk factors reflects the
genetic and environmental influence on the causal pathways of
familial CVD. In line with published data we found an association
with fibrinogen (a thrombotic risk factor), but not with hs-CRP, for
which literature is inconsistent [32,33,34,35,36].
Regarding the presence of atherosclerosis (a prognostically well-
validated non-invasive surrogate endpoint to assess cardiovascular
risk), the eFH low-risk group had significantly less atherosclerosis
compared to the eFH moderate- and high-risk groups. Although
other studies already demonstrated significantly more atheroscle-
rosis in patients with a FH of CVD [37,38]. Our study shows, for
the first time, that this is in large part due to significantly less
atherosclerosis in a ‘‘low-risk’’ group that can be readily identified
by eFH (but not by cFH), separating it from an intermediate group
(which would conventionally be classified as having a negative
FH). The eFH moderate risk group demonstrates almost identical
prevalence of atherosclerosis as the cFH positive group (corre-
sponding to the eFH high-risk group). This large eFH moderate-
risk group with a substantial atherosclerotic burden would be
overlooked when using the conventional FH definition.
Clinical Relevance
Although FH is an important risk factor for CVD and plays an
important role in medical practice, it is underused in CVD
prevention efforts [8,39]. Recent data from a randomized
controlled trial looking at the added value and feasibility of
systematically collecting FH, found that it increases the proportion
of persons identified as having high cardiovascular risk for further
targeted prevention (many risk factors are amenable to interven-
tion, by lifestyle or pharmacologically) [40,41]. FH also received
increased visibility as a risk qualifier in the new European
guidelines on CVD prevention, where a positive cFH is considered
to increase the 10-year risk of a fatal CV by 1.7-fold in women and
by 2.0-fold in men [42]. Conversely, it is suggested that 10-year
CVD risk (SCORE) may be lower in those with a FH of longevity.
Whilst knowledge of FH may not affect clinical decision making in
those at very high or very low predicted risk, it may aid in
discriminating risk among the very large group of subjects at
intermediate levels of predicted risk [43]. Since low-risk popula-
tions for CVD are gaining interest, our eFH low-risk group with a
more favourable risk profile and significantly less atherosclerosis,
could be an interesting phenotype for further study [44]. Yeboah
et al. recently studied novel risk markers, comprising (premature
and non-premature) FH of CHD in a first-degree relative, for
improvement in cardiovascular risk assessment in intermediate-
risk individuals. The authors found that FH was an independent
predictor of CHD/CVD in intermediate-risk individuals. Further-
more, besides coronary calcium score, FH performed the best for
CHD risk reclassification (NRI= 0.160). Interestingly, most of the
correct reclassification was based on subjects reclassified into a
lower risk category [45].
Intuitively, it seems likely that shared lifestyle risk factors
(smoking, diet, physical inactivity) represent (non-genetic) path-
ways through which FH influences risk of CVD. The literature is
inconsistent [36,46]; we found no clear associations between FH
and lifestyle parameters. It is possible that increased perception of
familial risk does not automatically lead to changed behaviour;
some people may even adopt a fatalistic outlook and make no
efforts at all to decrease their risk [47].
Figure 3. Adjusted odds ratios for presence of subclinical atherosclerosis according to the proposed new extended family history
definition (eFH) and the conventional definition (cFH). Odds ratios (95% confidence intervals) for the presence of subclinical atherosclerosis
were adjusted for age, sex, total cholesterol, HDL-cholesterol, systolic BP, smoking, DM and BMI. Taking the moderate-risk eFH group as the reference
category, odds ratios for prevalent atherosclerosis adjusted for classical risk factors mentioned above are 0.74 (95% CI 0.56–0.98) in the low-risk eFH
group versus the moderate-risk eFH group. There was no significant increase in prevalent atherosclerosis when comparing cFH positives versus
negatives or eFH high-risk versus moderate-risk categories.
doi:10.1371/journal.pone.0063185.g003
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Study Strengths and Limitations
The major limitation of the present study is the absence of
outcome data. We used a surrogate measure that is well validated
as a prognostic marker: presence of atherosclerosis. Furthermore,
it remains to be tested if our findings can be extrapolated to the
much younger (where relatives might not have aged sufficiently to
have suffered CV events) or older populations. One of the major
problems of defining and studying FH is that it is a ‘‘moving
target’’. A 52-year old man today that is eFH low-risk could end-
up tomorrow in the eFH high-risk category after his brother had a
myocardial infarction. Reassuringly, sensitivity analyses in our
cohort looking at the older and younger subjects (with corre-
spondingly older/younger family members) showed similar results.
A major strength is the population-based nature of the study,
combining a well-balanced, representative sample with stringent
methodology, and a broad and detailed array of carefully assessed
cardiovascular intermediate phenotypes.
Self-reported FH of CVD was not validated through medical
records, which is another potential limitation. Many, though not
all, previous studies showed that questionnaires considering FH of
CVD can be considered as accurate and people can correctly
report their FH for CVD [15,48,49,50,51]. Moreover, our
assessment of FH through self-report is similar to general practice,
thus the present findings can be generalized to the usual clinical
setting. We used a categorical definition rather than a (theoret-
ically attractive) continuous FH score, where entry is restricted to
more informative (i.e. larger) families and a single affected family
member is ruled out [50]. Considering the characteristics of our
study population families (average European family size), we
followed the recommendations from Silberberg et al., who
previously recommended that the use of categorical definitions
are more likely to be adequate in smaller families and few affected
relatives [52]. Finally, 13.6% of subjects could not be correctly
classified because of insufficiently accurate knowledge of their FH.
Conclusion
In this study, we designed and tested a novel extended family
history definition (Asklepios eFH) which: (1) better correlates with
metabolic risk factor burden and (2) independently predicts the
presence of subclinical atherosclerosis beyond conventional risk
factor burden, unlike cFH assessments and (3) shows significant
improvement in reclassification for the prediction of prevalent
atherosclerosis. Adding information on non-first degree relatives,
late occurrence of disease and number of affected relatives to the
FH construct improves the discrimination for cardiovascular risk
factors and atherosclerotic burden in order to better target
individuals for CVD prevention efforts. The new eFH definition
separates the cFH negative group into two categories: a large eFH
moderate-risk group, and a smaller eFH low-risk group. The latter
is a particularly interesting phenotype for further study, having a
more favourable risk profile and significantly less atherosclerosis
(odds ratio 0.74). There remain clear opportunities to refine and
increase the performance and informational content of this readily
available, simple, inexpensive tool.
Supporting Information
Questionnaire S1 The Asklepios Family History (FH)
Questionnaire. The Asklepios FH Questionnaire was created
specifically for this study. It provides data on the occurrence of
cardiovascular disease (CVD) in 4 generations of the respondent’s
genetic family (parents, grandparents, siblings and offspring). For
all family members, respondents provided the year of birth and the
year and cause of death. The questionnaire further queries for the
occurrence of fatal and nonfatal CVD events: myocardial
infarction, coronary revascularisation, peripheral vascular inter-
vention of inguinal or lower limb arteries, stroke, carotid
revascularisation or sudden cardiac death.
(PDF)
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